Virus News and Research

Latest Virus News and Research

Study: Birth cohort screening for HCV is cost effective in primary care setting

According to a new study being published early online in Annals of Internal Medicine, the flagship journal of the American College of Physicians, birth cohort screening for hepatitis C is cost effective in the primary care setting.

5 Nov 2011

Active ingredient in saffron shows promise against MS

Medical researchers at the University of Alberta have discovered that an active ingredient in the Persian spice saffron may be a potential treatment for diseases involving neuroinflammation, such as multiple sclerosis.

5 Nov 2011

Study finds increase in cervical cancer incidence among young British women

The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according to research that will be presented at the annual National Cancer Research Institute (NCRI) Cancer Conference in Liverpool which starts tomorrow.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011

'Medicine that grows' confronts antibiotics resistance

It's been called "the trots," "Montezuma's Revenge," "the runs" and worse. But no matter the name, when it strikes, victims wish for a medicine that could go straight to the offending bacteria to quickly knock it dead.

4 Nov 2011

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Longer looks: A doctor's dilemma on C-sections; apology for a death sparked a hospital's change

I was the obstetrician on hospital duty that Sunday morning, so I introduced myself and learned that the patient, pregnant with her first child, wished to have as few interventions as possible. Respecting her desire, we decided to reevaluate her in a few hours to see how her labor had progressed. But would she get her wish? ... the odds were greater than 1 in 4 that this woman would end up not with the natural delivery she wanted, but with a surgical delivery in one of the two operating rooms down the hall.

4 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011

Measles virus develops a strategy of diabolic elegance

Mayo Clinic researchers have discovered why measles, perhaps the most contagious viral disease in the world, spreads so quickly. The virus emerges in the trachea of its host, provoking a cough that fills the air with particles ready to infect the next host. The findings may also help in the fight against ovarian, breast and lung cancers.

3 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

UC Merced professor designs powerful chemical inhibitor against HIV

In a significant step toward reducing the threat of HIV, UC Merced Professor Patricia LiWang has designed what may be the most effective chemical inhibitor against infection of the virus.

3 Nov 2011

New version of chitosan effective in capturing flu virus

With flu season just around the corner, scientists are reporting development of a new material for the fiber in face masks, air conditioning filters and air cleaning filters that captures influenza viruses before they can get into people's eyes, noses and mouths and cause infection. The report on the fiber appears in ACS' journal Biomacromolecules.

3 Nov 2011

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

Final results from Medivir's TMC435 phase IIb study on genotype-1 hepatitis C

Medivir AB, a research-based speciality pharmaceutical company focused on infectious diseases, today announces final results from the ASPIRE study.

3 Nov 2011

Elevated body temperature helps certain types of immune cells to work better

With cold and flu season almost here, the next time you're sick, think twice before taking something for your fever. That's because scientists have found more evidence that elevated body temperature helps certain types of immune cells to work better.

2 Nov 2011

Massive clotting can destroy placenta and cause miscarriages

Researchers at St. Michael's Hospital have identified a potential new cause for unexplained miscarriages in mice.

2 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

Countries need vigilance, informed media coverage to achieve polio eradication

In this SciDev.Net editorial, T.V. Padma, regional coordinator for South Asia for the news service, recaps findings from the latest report of the Independent Monitoring Board of the Global Polio Eradication Initiative (GPEI), released last week, and writes, "Polio control in developing countries has received massive international support and funding, including free supplies of vaccines. Yet transmission of the virus remains. Clearly, there are problems other than funds."

1 Nov 2011